Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON
Top Cited Papers
- 1 November 2013
- journal article
- research article
- Published by Elsevier BV in Ophthalmology
- Vol. 120 (11), 2292-2299
- https://doi.org/10.1016/j.ophtha.2013.03.046
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular DegenerationOphthalmology, 2012
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2011
- A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: Clinical and Economic ImpactOphthalmology, 2010
- Natural History of Predominantly Classic, Minimally Classic, and Occult Subgroups in Exudative Age-related Macular DegenerationOphthalmology, 2009
- Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR StudyOphthalmology, 2009
- Ranibizumab Combined With Verteporfin Photodynamic Therapy in Neovascular Age-related Macular Degeneration (FOCUS): Year 2 ResultsAmerican Journal of Ophthalmology, 2008
- The Natural History and Prognosis of Neovascular Age-Related Macular Degeneration: A Systematic Review of the Literature and Meta-analysisOphthalmology, 2008
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2006
- NEOVASCULAR AGE-RELATED MACULAR DEGENERATIONRetina, 2005